Pfizer announced positive top-line results from the phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease driven by an immune attack on the hair follicles that causes hair loss on the scalp and can also affect the face and body. Ritlecitinib 50 mg and 30 mg achieved the primary efficacy endpoint of the study, namely the proportion of patients with less than or equal to 20 percent scalp hair loss after six months of treatment versus placebo.
Leaning into its new name, Bausch Health is laying the groundwork for a pipeline expansion. It’s forking over $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, including its retinal disease med risuteganib. If Allegro pulls off another financing, Bausch will hand over the remaining $40 million, likely in 2021.
A recent market study throws light on some of the leading factors that are likely to influence the growth of the Frovatriptan market in the upcoming decade. The well-researched market study touches upon the growth potential of various budding market players in the current Frovatriptan market landscape. Moreover, established players, stakeholders, and investors can leverage the data in the report to formulate effective growth strategies.
Complete study of the global Frovatriptan market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Frovatriptan industry. Research techniques like PESTLE and Porter’s Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Frovatriptan production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.